< Back to latest news & events

Event

5th Annual Microbiome & Probiotic Conference 2023

January 2023

The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February.

This conference will enable you to learn about microbial innovation and apply the new microbiome findings along with the regulatory pathways for better therapeutic development. The conference will also allow you to connect with biotech, pharma, academicians, and investors to discuss the most ingenious research and technological advances.

HGF Partner & Patent Attorney Craig Thomson will deliver a virtual session on ‘An IP Strategy for Microbiome Innovators is not a list of patent rights‘.

This session will include:

  • Building a microbiome relevant IP strategy
  • Ensuring the IP strategy is commercially relevant to your business
  • Using an IP strategy for encouraging investment

Find out more about the conference by clicking the button below:

FIND OUT MORE

Attendees

Craig
Thomson

Latest updates

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

IP Ingredients: The not so "Impossible" Burger

Meat alternatives are a hot topic with the increase in popularity of vegetarianism and veganism, highlighted by this month being “veganuary”.  However, at time when meat alternatives are coming under …

Read article

WTR 1000 2025

We are proud to announce that our European trade mark team has been recognised in the World Trade Mark Review 1000 2025. The firm is also proud to have 19 …

Read article

Court of Appeal Confirms No Second Medical Use SPCs in UK

Merck Serono SA  v  The Comptroller-General of Patents, Designs, and Trade Marks – Lewison LJ, Arnold LJ and Birss LJ – [2025] EWCA Civ 45 – 28 January 2025 The …

Read article

T 0295/22: Apremilast decision highlights hopes and challenges for broad second medical use claims

This case provides insight to the EPO’s interpretation of administration features in second medical use claims. Whilst the door appears to be open for broader second medical use claims, they …

Read article

T 1418/22: Acalabrutinib provides guidance on establishing inventiveness of polymorphs at the EPO

The EPO Board of Appeal’s decision in T 1418/22 gives useful guidance on the inventiveness of polymorph claims in Europe. Starting from a known amorphous form, a specific crystalline form …

Read article

HGF Celebrates Two Nominations at the Women and Diversity in Law Awards

We are proud to share that we have been nominated for two awards at The Women and Diversity in Law Awards which will take place on 18th March at Hilton …

Read article
See all updates